DK3106170T3 - Nedbrydelige clostridiumtoksiner - Google Patents

Nedbrydelige clostridiumtoksiner Download PDF

Info

Publication number: DK3106170T3
Authority: DK; Denmark
Prior art keywords: degradable; clostridium toxins; clostridium; toxins; degradable clostridium
Prior art date: 2010-05-20

Application number

DK16181227.6T

Other languages

English (en)

Inventor

Lance E Steward

Sanjiv Ghanshani

Ester Fernandez-Salas

Marcella A Gilmore

Joseph Francis

Kei Roger Aoki

Original Assignee

Allergan Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-05-20

Filing date

2011-05-19

Publication date

2020-07-13

2011-05-19 Application filed by Allergan Inc filed Critical Allergan Inc

2020-07-13 Application granted granted Critical

2020-07-13 Publication of DK3106170T3 publication Critical patent/DK3106170T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Genetics & Genomics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
General Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Biophysics (AREA)
Immunology (AREA)
Toxicology (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Dermatology (AREA)
Ophthalmology & Optometry (AREA)
Orthopedic Medicine & Surgery (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)

DK16181227.6T 2010-05-20 2011-05-19 Nedbrydelige clostridiumtoksiner DK3106170T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US34657810P	2010-05-20	2010-05-20
EP13176290.8A EP2650003B1 (en)	2010-05-20	2011-05-19	Degradable clostridial toxins

Publications (1)

Publication Number	Publication Date
DK3106170T3 true DK3106170T3 (da)	2020-07-13

Family

ID=44484018

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
DK16181227.6T DK3106170T3 (da)	2010-05-20	2011-05-19	Nedbrydelige clostridiumtoksiner
DK11724483.0T DK2571509T3 (da)	2010-05-20	2011-05-19	Nedbrydelige clostridiumtoksiner
DK13176290.8T DK2650003T3 (da)	2010-05-20	2011-05-19	Nedbrydelige clostridiumtoksiner

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
DK11724483.0T DK2571509T3 (da)	2010-05-20	2011-05-19	Nedbrydelige clostridiumtoksiner
DK13176290.8T DK2650003T3 (da)	2010-05-20	2011-05-19	Nedbrydelige clostridiumtoksiner

Country Status (20)

Country	Link
US (13)	US8512992B2 (da)
EP (3)	EP2571509B1 (da)
JP (4)	JP6148979B2 (da)
KR (4)	KR102321664B1 (da)
CN (1)	CN103228286B (da)
AR (1)	AR081407A1 (da)
AU (1)	AU2011255525B2 (da)
BR (1)	BR112012029666A2 (da)
CA (1)	CA2799969C (da)
DK (3)	DK3106170T3 (da)
ES (3)	ES2813650T3 (da)
IL (1)	IL223100B (da)
MX (2)	MX369263B (da)
NZ (2)	NZ703378A (da)
RU (1)	RU2561465C2 (da)
SG (2)	SG10201506567UA (da)
TW (1)	TWI516594B (da)
UA (1)	UA108646C2 (da)
WO (1)	WO2011146704A1 (da)
ZA (1)	ZA201208753B (da)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2750371B2 (ja)	1989-05-12	1998-05-13	触媒化成工業株式会社	接触分解用触媒組成物およびそれを使用した重質炭化水素油の接触分解方法
JP6148979B2 (ja)	2010-05-20	2017-06-14	アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ	分解性クロストリジウム毒素
ES2625847T3 (es) *	2011-11-04	2017-07-20	Lipotec, S.A.	Péptidos que inhiben la actividad de receptores activados y su uso en composiciones cosméticas o farmacéuticas
EP2798077A2 (en)	2011-12-31	2014-11-05	Allergan, Inc.	Highly Sensitive Cell-Based Assay to Detect the Presence of Active Botulinum Neurotoxin Serotype-A
EA035323B1 (ru)	2012-01-12	2020-05-28	Биовератив Терапьютикс Инк.	Полипептиды химерного фактора viii и их применение
HRP20221531T1 (hr)	2012-02-15	2023-02-17	Bioverativ Therapeutics Inc.	Pripravci faktora viii i postupci dobivanja i korištenja istih
LT2822577T (lt)	2012-02-15	2019-03-25	Bioverativ Therapeutics Inc.	Rekombinantiniai faktoriaus viii baltymai
US10253089B2 (en) *	2012-05-30	2019-04-09	University Of Utah Research Foundation	Matrix metalloproteinase cleavable protein polymers for cancer gene therapy
US10138291B2 (en)	2012-07-11	2018-11-27	Bioverativ Therapeutics Inc.	Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof
US20140170132A1 (en)	2012-12-18	2014-06-19	Allergan, Inc.	Prophylatic treatment of herpes recurrence
CN104212833A (zh) *	2013-05-30	2014-12-17	江苏大学	一种新型转基因质粒载体及其构建方法、体内含新型重组基因家蚕的培育方法
WO2014210547A1 (en) *	2013-06-28	2014-12-31	Biogen Idec Ma Inc.	Thrombin cleavable linker
GB201312317D0 (en) *	2013-07-09	2013-08-21	Syntaxin Ltd	Cationic neurotoxins
EP3033097B1 (en)	2013-08-14	2021-03-10	Bioverativ Therapeutics Inc.	Factor viii-xten fusions and uses thereof
IL291329B1 (en) *	2013-09-25	2025-09-01	Cytomx Therapeutics Inc	Polypeptides that can be determined in matrix metalloproteinases and uses thereof
US9216210B2 (en)	2013-12-23	2015-12-22	Dublin City University	Multiprotease therapeutics for chronic pain
DK3091997T5 (da)	2014-01-10	2024-10-14	Bioverativ Therapeutics Inc	Kimære faktor viii-proteiner og anvendelser deraf
CN106459153B (zh) *	2014-01-31	2021-12-21	西托姆克斯治疗公司	蛋白裂解酶和u型纤溶酶原激活物的底物和其它可裂解部分及其使用方法
US9943576B2 (en)	2014-04-30	2018-04-17	Allergan, Inc.	Formulations of biologics for intravesical instillation
BR112017001888A2 (pt)	2014-07-31	2017-11-28	Allergan Inc	formulações biológicas para instilação intravesical
RU2585494C2 (ru) *	2014-09-17	2016-05-27	Федеральное государственное бюджетное учреждение "Государственный научный центр Институт иммунологии" Федерального медико-биологического агентства России	Рекомбинантный белок rec-mp, содержащий в своем составе последовательности миелопептидов для лечения вторичных иммунодефицитных состояний
US9616114B1 (en)	2014-09-18	2017-04-11	David Gordon Bermudes	Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
MA41374A (fr)	2015-01-20	2017-11-28	Cytomx Therapeutics Inc	Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
CN115925835A (zh)	2015-03-26	2023-04-07	哈佛大学校长及研究员协会	工程改造的肉毒杆菌神经毒素
GB201505306D0 (en) *	2015-03-27	2015-05-13	Ipsen Biopharm Ltd	Chimeric polypeptides
US10676723B2 (en)	2015-05-11	2020-06-09	David Gordon Bermudes	Chimeric protein toxins for expression by therapeutic bacteria
GB201607901D0 (en)	2016-05-05	2016-06-22	Ipsen Biopharm Ltd	Chimeric neurotoxins
PL3481852T3 (pl) *	2016-07-08	2023-07-24	Children's Medical Center Corporation	Nowa neurotoksyna botulinowa i jej pochodne
US11117935B2 (en)	2016-08-24	2021-09-14	President And Fellows Of Harvard College	Engineered botulinum neurotoxin
US11337994B2 (en)	2016-09-15	2022-05-24	University Of Utah Research Foundation	In situ gelling compositions for the treatment or prevention of inflammation and tissue damage
WO2018102743A1 (en)	2016-12-02	2018-06-07	Bioverativ Therapeutics Inc.	Methods of treating hemophilic arthropathy using chimeric clotting factors
US11180535B1 (en)	2016-12-07	2021-11-23	David Gordon Bermudes	Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en)	2016-12-07	2021-09-28	David Gordon Bermudes	Chimeric protein toxins for expression by therapeutic bacteria
US10849914B2 (en)	2017-06-12	2020-12-01	University Of Utah Research Foundation	Methods for producing chemoembolic agents for the delivery of anti-cancer agents
AU2018314269B2 (en) *	2017-08-11	2022-12-08	University Of Kentucky Research Foundation	Anti-neurodegenerative therapeutic, method of manufacture, and use
US11149262B2 (en)	2017-12-20	2021-10-19	Alleergan, Inc.	Botulinum toxin cell binding domain polypeptides and methods of use for skin rejuvenation
US11707510B2 (en) *	2018-02-16	2023-07-25	Preclinics Discovery Gmbh	Nucleic acid-based botulinum neurotoxin for therapeutic use
RS66972B1 (sr)	2018-05-18	2025-07-31	Bioverativ Therapeutics Inc	Metode lečenja hemofilije a
CA3120327A1 (en)	2018-12-06	2020-06-11	Cytomx Therapeutics, Inc.	Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
GB202104294D0 (en) *	2021-03-26	2021-05-12	Ipsen Biopharm Ltd	Clostridial neurotoxins comprising an exogenous activation loop
US12077607B2 (en)	2021-09-23	2024-09-03	University Of Utah Research Foundation	Functional and therapeutic effects of PAR4 cleavage by cathepsin G
KR102728382B1 (ko) *	2022-10-12	2024-11-14	주식회사 알케미어	보툴리눔 독소의 경쇄 변이체
KR20250122877A (ko) *	2024-02-07	2025-08-14	주식회사 알케미어	보툴리눔 독소 e형의 경쇄 변이체

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69133064T2 (de)	1990-02-26	2003-03-06	The Board Of Trustees Of The Leland Stanford Junior University, Stanford	Identifizierung und expression von insekten-steroidrezeptor-dns-sequenzen
US5364791A (en)	1992-05-14	1994-11-15	Elisabetta Vegeto	Progesterone receptor having C. terminal hormone binding domain truncations
JPH07509694A (ja)	1992-05-14	1995-10-26	ベイラー・カレッジ・オブ・メディシン	突然変異したステロイドホルモン受容体，その使用方法および遺伝子治療のための分子スイッチ
US5464758A (en)	1993-06-14	1995-11-07	Gossen; Manfred	Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5814618A (en)	1993-06-14	1998-09-29	Basf Aktiengesellschaft	Methods for regulating gene expression
GB9508204D0 (en)	1995-04-21	1995-06-07	Speywood Lab Ltd	A novel agent able to modify peripheral afferent function
GB9617671D0 (en)	1996-08-23	1996-10-02	Microbiological Res Authority	Recombinant toxin fragments
GB9818548D0 (en)	1998-08-25	1998-10-21	Microbiological Res Authority	Treatment of mucas hypersecretion
US6776990B2 (en)	1999-04-08	2004-08-17	Allergan, Inc.	Methods and compositions for the treatment of pancreatitis
CA2380457A1 (en)	1999-08-25	2001-03-01	Allergan Sales, Inc.	Activatable recombinant neurotoxins
US20090018081A1 (en)	1999-08-25	2009-01-15	Allergan, Inc.	Activatable clostridial toxins
US7740868B2 (en)	1999-08-25	2010-06-22	Allergan, Inc.	Activatable clostridial toxins
US20030180289A1 (en)	1999-09-23	2003-09-25	Foster Keith Alan	Inhibition of secretion from non-neuronal cells
US6500436B2 (en)	2000-01-19	2002-12-31	Allergan, Inc.	Clostridial toxin derivatives and methods for treating pain
US7138127B1 (en)	2000-01-19	2006-11-21	Allergan, Inc.	Clostridial toxin derivatives and methods for treating pain
US7491799B2 (en)	2000-07-21	2009-02-17	Allergan, Inc.	Modified botulinum neurotoxins
US20030219462A1 (en)	2000-07-21	2003-11-27	Allergan Sales, Inc	Clostridial neurotoxin compositions and modified clostridial neurotoxins
US6903187B1 (en)	2000-07-21	2005-06-07	Allergan, Inc.	Leucine-based motif and clostridial neurotoxins
US7273722B2 (en) *	2000-11-29	2007-09-25	Allergan, Inc.	Neurotoxins with enhanced target specificity
GB0321344D0 (en)	2003-09-11	2003-10-15	Health Prot Agency	Re-targeted toxin conjugates
JP4262072B2 (ja)	2003-12-05	2009-05-13	株式会社日立製作所	自動車用補助機器制御装置
US7811584B2 (en)	2004-06-30	2010-10-12	Allergan, Inc.	Multivalent clostridial toxins
US7514088B2 (en)	2005-03-15	2009-04-07	Allergan, Inc.	Multivalent Clostridial toxin derivatives and methods of their use
US20060024331A1 (en) *	2004-08-02	2006-02-02	Ester Fernandez-Salas	Toxin compounds with enhanced membrane translocation characteristics
WO2006026780A1 (en)	2004-09-01	2006-03-09	Allergan, Inc.	Degradable clostridial toxins
GB0426394D0 (en)	2004-12-01	2005-01-05	Health Prot Agency	Fusion proteins
US7659092B2 (en)	2004-12-01	2010-02-09	Syntaxin, Ltd.	Fusion proteins
GB0426397D0 (en)	2004-12-01	2005-01-05	Health Prot Agency	Fusion proteins
CA2601592A1 (en)	2005-03-15	2006-09-28	Allergan, Inc.	Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
DK1926744T4 (da) *	2005-09-19	2019-01-28	Allergan Inc	Clostridium toksin-aktiverbare clostridiale toksiner
WO2007106115A1 (en)	2006-03-14	2007-09-20	Allergan, Inc.	Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
EP1834962A1 (de) *	2006-03-15	2007-09-19	Biotecon Therapeutics GmbH	PEGyliertes mutiertes Clostridium botulinum Toxin
EP2038299A2 (en)	2006-07-11	2009-03-25	Allergan, Inc.	Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells
WO2008008803A2 (en)	2006-07-11	2008-01-17	Allergan, Inc.	Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
US8993295B2 (en) *	2006-07-20	2015-03-31	The General Hospital Corporation	Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting
US7692222B2 (en)	2006-11-07	2010-04-06	Raytheon Company	Atomic layer deposition in the formation of gate structures for III-V semiconductor
RU2010120016A (ru) *	2007-10-23	2011-11-27	Аллерган, Инк. (Us)	Способы лечения хронического нейрогенного воспаления с применением модифицированных клостридиальных токсинов
GB0903006D0 (en) *	2009-02-23	2009-04-08	Syntaxin Ltd	Modified non-cytotoxic proteases
JP6148979B2 (ja) *	2010-05-20	2017-06-14	アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ	分解性クロストリジウム毒素

2011
- 2011-05-19 JP JP2013511353A patent/JP6148979B2/ja not_active Expired - Fee Related
- 2011-05-19 ES ES16181227T patent/ES2813650T3/es active Active
- 2011-05-19 DK DK16181227.6T patent/DK3106170T3/da active
- 2011-05-19 EP EP11724483.0A patent/EP2571509B1/en active Active
- 2011-05-19 UA UAA201214593A patent/UA108646C2/ru unknown
- 2011-05-19 NZ NZ703378A patent/NZ703378A/en not_active IP Right Cessation
- 2011-05-19 BR BR112012029666-3A patent/BR112012029666A2/pt not_active Application Discontinuation
- 2011-05-19 DK DK11724483.0T patent/DK2571509T3/da active
- 2011-05-19 EP EP16181227.6A patent/EP3106170B1/en active Active
- 2011-05-19 KR KR1020207028393A patent/KR102321664B1/ko not_active Expired - Fee Related
- 2011-05-19 SG SG10201506567UA patent/SG10201506567UA/en unknown
- 2011-05-19 CN CN201180035613.3A patent/CN103228286B/zh not_active Expired - Fee Related
- 2011-05-19 EP EP13176290.8A patent/EP2650003B1/en active Active
- 2011-05-19 MX MX2015015117A patent/MX369263B/es unknown
- 2011-05-19 MX MX2012013381A patent/MX2012013381A/es active IP Right Grant
- 2011-05-19 SG SG2012085114A patent/SG185663A1/en unknown
- 2011-05-19 ES ES13176290.8T patent/ES2600463T3/es active Active
- 2011-05-19 KR KR1020217035259A patent/KR20210132753A/ko not_active Withdrawn
- 2011-05-19 NZ NZ604322A patent/NZ604322A/en not_active IP Right Cessation
- 2011-05-19 RU RU2012154862/10A patent/RU2561465C2/ru active
- 2011-05-19 ES ES11724483.0T patent/ES2596128T3/es active Active
- 2011-05-19 KR KR1020197001617A patent/KR102164166B1/ko not_active Expired - Fee Related
- 2011-05-19 KR KR1020127033131A patent/KR101942106B1/ko not_active Expired - Fee Related
- 2011-05-19 WO PCT/US2011/037131 patent/WO2011146704A1/en not_active Ceased
- 2011-05-19 DK DK13176290.8T patent/DK2650003T3/da active
- 2011-05-19 CA CA2799969A patent/CA2799969C/en not_active Expired - Fee Related
- 2011-05-19 AU AU2011255525A patent/AU2011255525B2/en not_active Ceased
- 2011-05-20 US US13/112,844 patent/US8512992B2/en not_active Expired - Fee Related
- 2011-05-20 AR ARP110101742A patent/AR081407A1/es not_active Application Discontinuation
- 2011-05-20 TW TW100117869A patent/TWI516594B/zh not_active IP Right Cessation
2012
- 2012-11-18 IL IL223100A patent/IL223100B/en active IP Right Grant
- 2012-11-21 ZA ZA2012/08753A patent/ZA201208753B/en unknown
2013
- 2013-03-18 US US13/846,364 patent/US8841111B2/en active Active
- 2013-03-18 US US13/846,338 patent/US8685693B2/en active Active
- 2013-03-18 US US13/846,307 patent/US8685692B2/en active Active
- 2013-08-16 US US13/969,148 patent/US8697413B2/en active Active
- 2013-08-16 US US13/969,174 patent/US8697414B2/en active Active
- 2013-11-21 US US14/086,840 patent/US9279116B2/en active Active
- 2013-11-22 US US14/087,952 patent/US9284545B2/en active Active
- 2013-11-22 US US14/088,022 patent/US9297003B2/en active Active
2015
- 2015-08-07 JP JP2015157372A patent/JP6220830B2/ja not_active Expired - Fee Related
2016
- 2016-03-28 US US15/082,635 patent/US9850476B2/en active Active
2017
- 2017-07-06 JP JP2017133024A patent/JP6467000B2/ja not_active Expired - Fee Related
- 2017-12-18 US US15/845,572 patent/US10501731B2/en active Active
2019
- 2019-01-10 JP JP2019002677A patent/JP6644177B2/ja not_active Expired - Fee Related
- 2019-12-09 US US16/707,187 patent/US20200190496A1/en not_active Abandoned
2022
- 2022-09-23 US US17/934,914 patent/US20240018500A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20240018500A1 (en)	2024-01-18
CN103228286B (zh)	2018-01-02
DK2650003T3 (da)	2016-11-28
KR20210132753A (ko)	2021-11-04
US20130273633A1 (en)	2013-10-17
KR20200118234A (ko)	2020-10-14
TW201142026A (en)	2011-12-01
US10501731B2 (en)	2019-12-10
SG185663A1 (en)	2012-12-28
EP2650003B1 (en)	2016-07-27
US20130330807A1 (en)	2013-12-12
CA2799969C (en)	2019-06-25
RU2561465C2 (ru)	2015-08-27
ZA201208753B (en)	2013-09-25
US9850476B2 (en)	2017-12-26
EP2650003A1 (en)	2013-10-16
KR101942106B1 (ko)	2019-01-25
US20160201046A1 (en)	2016-07-14
US8697413B2 (en)	2014-04-15
US20200190496A1 (en)	2020-06-18
MX369263B (es)	2019-11-04
AU2011255525B2 (en)	2015-09-10
NZ703378A (en)	2016-10-28
EP2571509B1 (en)	2016-07-06
US8685692B2 (en)	2014-04-01
AR081407A1 (es)	2012-08-29
US20140127783A1 (en)	2014-05-08
US20110287517A1 (en)	2011-11-24
ES2600463T3 (es)	2017-02-09
EP3106170B1 (en)	2020-04-08
JP6148979B2 (ja)	2017-06-14
EP3106170A1 (en)	2016-12-21
US9284545B2 (en)	2016-03-15
TWI516594B (zh)	2016-01-11
ES2813650T3 (es)	2021-03-24
HK1180592A1 (zh)	2013-10-25
US8685693B2 (en)	2014-04-01
US20130330806A1 (en)	2013-12-12
WO2011146704A1 (en)	2011-11-24
US20180119126A1 (en)	2018-05-03
KR20190010720A (ko)	2019-01-30
US8512992B2 (en)	2013-08-20
ES2596128T3 (es)	2017-01-05
US8841111B2 (en)	2014-09-23
NZ604322A (en)	2015-01-30
JP2015193669A (ja)	2015-11-05
US20130196414A1 (en)	2013-08-01
US20140227740A1 (en)	2014-08-14
JP2013529213A (ja)	2013-07-18
CA2799969A1 (en)	2011-11-24
JP2019088296A (ja)	2019-06-13
UA108646C2 (xx)	2015-05-25
CN103228286A (zh)	2013-07-31
US9279116B2 (en)	2016-03-08
SG10201506567UA (en)	2015-10-29
US9297003B2 (en)	2016-03-29
KR20130054967A (ko)	2013-05-27
JP6644177B2 (ja)	2020-02-12
US20140220627A1 (en)	2014-08-07
US20130288334A1 (en)	2013-10-31
JP6220830B2 (ja)	2017-10-25
MX2012013381A (es)	2013-02-21
EP2571509A1 (en)	2013-03-27
KR102164166B1 (ko)	2020-10-13
BR112012029666A2 (pt)	2020-10-06
RU2012154862A (ru)	2014-06-27
DK2571509T3 (da)	2016-10-24
JP6467000B2 (ja)	2019-02-06
KR102321664B1 (ko)	2021-11-04
JP2018012696A (ja)	2018-01-25
IL223100A0 (en)	2013-02-03
AU2011255525A1 (en)	2012-12-20
US8697414B2 (en)	2014-04-15
IL223100B (en)	2018-02-28

Publication	Publication Date	Title
DK3106170T3 (da)	2020-07-13	Nedbrydelige clostridiumtoksiner
BR112013015783A2 (pt)	2018-05-29	autoinjetor.
DK2536452T3 (da)	2019-01-02	Autoinjektor
DK2585140T3 (da)	2019-10-14	Autoinjektor
DK2585137T3 (da)	2019-11-04	Autoinjektor
BR112013008072A2 (pt)	2016-06-14	autoinjetor
BR112013008401A2 (pt)	2016-06-21	autoinjetor
DK2654833T3 (da)	2019-05-20	Autoinjektor
BR112012028556A2 (pt)	2014-04-01	Indóis
DE102011100241A8 (de)	2012-03-01	Nitridhalbleiterbauteil
CR20130111A (es)	2013-05-29	Triazina-oxidiazoles
DE10170954T8 (de)	2013-04-25	Mikrowellendruckgarer
DK2654842T3 (da)	2020-01-06	Autoinjektor
BR112013007610A2 (pt)	2016-07-26	benzoxazinonas herbecidas
DE112011104226A5 (de)	2013-09-26	Käfigmutter
DE102011117046A8 (de)	2012-12-27	Doppelkupplungswindungsgetriebe
DE112011101226A5 (de)	2013-01-24	Linearwegmesssystem
DE112011102080A5 (de)	2013-04-11	Kupplungszentralausrücker
DK2442899T3 (da)	2013-10-07	Rotorskive
DE102010038420A8 (de)	2013-01-10	Reinigungungsvorrichtung
DE112011101333A5 (de)	2013-01-24	Parkouraufbau
DE102011002623A8 (de)	2012-02-02	Ventilsteuerzeitversteller
DE112011102711A5 (de)	2013-05-29	Hydrostataktor
DE102010035554B8 (de)	2014-12-24	Fußtüröffner
DE102010019119B8 (de)	2013-01-31	Cuttermesser